View Financial HealthVerici Dx 배당 및 자사주 매입배당 기준 점검 0/6Verici Dx 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 20Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant RecipientsVerici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.공시 • Apr 18Verici Dx plc Appoints Keith Gilliard as Senior Director of SalesVerici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals.공시 • Oct 08Verici Dx plc Announces Board Changes, Effective October 6, 2025Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company.공시 • Jul 29Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 86,286,792 Price\Range: £0.005공시 • Jul 22+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.005공시 • Jul 21Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000,000 Price\Range: £0.005 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,439,092 Price\Range: £0.005 Transaction Features: Regulation S; Subsequent Direct Listing공시 • Jun 30Verici Dx plc, Annual General Meeting, Jul 29, 2025Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom공시 • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.공시 • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024공시 • Jun 08Verici Dx plc, Annual General Meeting, Jun 25, 2024Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom공시 • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024공시 • Feb 14Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing공시 • Jan 25+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing공시 • Jan 24Verici Dx plc, Annual General Meeting, Feb 19, 2024Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission.공시 • Jan 08Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.공시 • Jul 22Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 StatesVerici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need.공시 • Jul 04Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for ClaravaVerici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population.공시 • Jun 06Verici Dx plc, Annual General Meeting, Jun 29, 2023Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdom공시 • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 VRCD.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: VRCD.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Verici Dx 배당 수익률 vs 시장VRCD.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (VRCD.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (VRCD.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VRCD.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VRCD.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VRCD.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: VRCD.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 18:49종가2026/03/12 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Verici Dx plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 20Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant RecipientsVerici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.
공시 • Apr 18Verici Dx plc Appoints Keith Gilliard as Senior Director of SalesVerici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals.
공시 • Oct 08Verici Dx plc Announces Board Changes, Effective October 6, 2025Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company.
공시 • Jul 29Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 86,286,792 Price\Range: £0.005
공시 • Jul 22+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.005
공시 • Jul 21Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000,000 Price\Range: £0.005 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,439,092 Price\Range: £0.005 Transaction Features: Regulation S; Subsequent Direct Listing
공시 • Jun 30Verici Dx plc, Annual General Meeting, Jul 29, 2025Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom
공시 • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.
공시 • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024
공시 • Jun 08Verici Dx plc, Annual General Meeting, Jun 25, 2024Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom
공시 • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024
공시 • Feb 14Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing
공시 • Jan 25+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing
공시 • Jan 24Verici Dx plc, Annual General Meeting, Feb 19, 2024Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission.
공시 • Jan 08Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.
공시 • Jul 22Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 StatesVerici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need.
공시 • Jul 04Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for ClaravaVerici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population.
공시 • Jun 06Verici Dx plc, Annual General Meeting, Jun 29, 2023Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdom
공시 • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023